- The coronavirus vaccine race delivers more promising news, as the US invested $1.2 billion to speed up development and secure 300 million doses for the breakthrough Oxford candidate.
- The novel coronavirus drug proved in pre-clinical trials that it’s effective and safe, and it’s now in human testing.
- AstraZeneca has licensed the medicine and is in talks to significantly expand manufacturing capacity.
- Visit BGR’s homepage for more stories.
The novel coronavirus health crisis isn’t going away anytime soon, but we’re getting more and more promising reports about potential treatments that could cure or even prevent COVID-19. Vaccines, as in more than one candidate, are the miracle drugs that can prevent infections with SARS-CoV-2, but they’re up to a year away from reaching the masses. At best, the first candidates will be approved for emergency use as soon as September. But there’s no guarantee these medicines will work on humans despite the promising data coming from pre-clinical and clinical trials.
If the Oxford breakthrough drug ChAdOx1 nCoV-19 is efficient and safe, the US will buy as many as 300 million units from the first batch of a billion doses that AstraZeneca can manufacture. To secure that supply, the US government pledged $1.2 billion towards the pharmaceutical company’s coronavirus vaccine development efforts.
Today’s Top Deals
- These 10 Amazon deals are only available to Prime members
- 70¢ coronavirus face masks are flying off the shelves again at Amazon
- Try these headphones for $40 before you buy $400 Bose noise cancelling headphones
Trending Right Now:
- This is the best coronavirus news we’ve seen all month
- Stimulus checks are great, but a new idea would give everyone $10,000 in credit card debt relief
- Coronavirus second wave: This site tells you if it’s too soon for your state to reopen
US secures 300M doses of coronavirus vaccine candidate from Oxford originally appeared on BGR.com on Thu, 21 May 2020 at 14:42:40 EDT. Please see our terms for use of feeds.
Read more here:: Boy Genius Report